During her lifetime she was unable to persuade obstetricians at Kobe to trial the antifibrinolytic agent, which had become a drug on the WHO list of essential medicines in 2009.

The Okamotos found it was 27 times as powerful and thus a promising hemostatic agent and published their findings in the Keio Journal of Medicine in 1962.

[1] Tranexamic acid's value remained unappreciated for years, and it was not until 2009, that it was included on the WHO list of essential medicines to be used during cardiac surgery.

[4] Also in 2010, the WOMAN (World Maternal Antifibrinolytic) trial began, a randomised, double-blind, placebo-controlled study of tranexamic acid in 20 060 women with post-partum haemorrhage.

Enrollment was completed in 2016,[5] and in April 2017, the results were published and showed that tranexamic acid reduced death in the 10,036 treated women versus the 9985 on placebo with no adverse effects.

[1] However she and a coworker were asked to leave a pediatric conference, because the event was not for "women and children" (onna kodomo),[1] a term she said in a 2012 interview she had never heard before.

[7]: 7:30 Ian Roberts, Professor of Epidemiology and Public Health at the London School of Hygiene & Tropical Medicine who had been coordinating the 2010 trauma trial visited Okamoto, then about 92 in Japan.